X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
human necessities (183) 183
hygiene (183) 183
medical or veterinary science (183) 183
preparations for medical, dental, or toilet purposes (183) 183
general tagging of cross-sectional technologies spanning over several sections of the ipc (173) 173
general tagging of new technological developments (173) 173
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (173) 173
technologies for adaptation to climate change (173) 173
technologies or applications for mitigation or adaptation againstclimate change (173) 173
specific therapeutic activity of chemical compounds ormedicinal preparations (147) 147
investigating or analysing materials by determining theirchemical or physical properties (71) 71
measuring (71) 71
physics (71) 71
testing (71) 71
humans (32) 32
index medicus (26) 26
female (25) 25
male (24) 24
hiv infections - drug therapy (20) 20
infectious diseases (19) 19
adult (18) 18
cobicistat (15) 15
immunology (15) 15
double-blind method (14) 14
middle aged (13) 13
tenofovir (12) 12
antiretroviral drugs (11) 11
chemistry (11) 11
emtricitabine (11) 11
heterocyclic compounds (11) 11
human immunodeficiency virus--hiv (11) 11
metallurgy (11) 11
organic chemistry (11) 11
agriculture (10) 10
aids/hiv (10) 10
animal husbandry (10) 10
anti-hiv agents - administration & dosage (10) 10
biocides, e.g. as disinfectants, as pesticides, as herbicides (10) 10
co-formulated elvitegravir (10) 10
double-blind (10) 10
fishing (10) 10
forestry (10) 10
hunting (10) 10
initial treatment (10) 10
pest repellants or attractants (10) 10
plant growth regulators (10) 10
preservation of bodies of humans or animals or plants or partsthereof (10) 10
trapping (10) 10
treatment outcome (10) 10
drug therapy (9) 9
hiv (9) 9
hiv infections - virology (9) 9
abridged index medicus (8) 8
adenine - analogs & derivatives (8) 8
aged (8) 8
anti-hiv agents - therapeutic use (8) 8
clinical trials (8) 8
deoxycytidine - analogs & derivatives (8) 8
disoproxil fumarate (8) 8
drug combinations (8) 8
quinolones - administration & dosage (8) 8
carbamates - administration & dosage (7) 7
efavirenz (7) 7
quinolones - therapeutic use (7) 7
research (7) 7
ritonavir (7) 7
ritonavir - therapeutic use (7) 7
rna, viral - blood (7) 7
safety (7) 7
thiazoles - administration & dosage (7) 7
adenine - administration & dosage (6) 6
adenine - therapeutic use (6) 6
carbamates - therapeutic use (6) 6
deoxycytidine - administration & dosage (6) 6
deoxycytidine - therapeutic use (6) 6
efficacy (6) 6
elvitegravir (6) 6
hiv-1 (6) 6
non-inferiority trial (6) 6
organophosphonates - administration & dosage (6) 6
organophosphonates - therapeutic use (6) 6
raltegravir (6) 6
ritonavir - administration & dosage (6) 6
thiazoles - therapeutic use (6) 6
time factors (6) 6
treatment-naive (6) 6
anti-hiv agents - adverse effects (5) 5
atazanavir sulfate (5) 5
cobicistat - administration & dosage (5) 5
comparative analysis (5) 5
drug therapy, combination (5) 5
hiv infection (5) 5
hiv-1 - drug effects (5) 5
hiv-1 infection analysis (5) 5
medicine, general & internal (5) 5
patients (5) 5
pharmacokinetics (5) 5
phase-3 (5) 5
protease inhibitors (5) 5
ribonucleic acid--rna (5) 5
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (224) 224
French (29) 29
German (21) 21
Spanish (20) 20
Chinese (13) 13
Korean (6) 6
Portuguese (6) 6
Croatian (4) 4
Danish (4) 4
Greek (4) 4
Serbian (4) 4
Slovenian (4) 4
Russian (3) 3
Arabic (2) 2
Italian (2) 2
Japanese (2) 2
Polish (2) 2
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9779, pp. 1760 - 1769
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 96 - 100
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs... 
HIV | cobicistat | phase 3 randomized trial | safety | efficacy | stribild | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | NON-INFERIORITY TRIAL | PHASE-3 | IMMUNOLOGY | TREATMENT-NAIVE | EFAVIRENZ | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Humans | Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | Male | RNA, Viral - blood | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Deoxycytidine - therapeutic use | Adenine - adverse effects | HIV-1 - physiology | Quinolones - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Oxazines - adverse effects | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Oxazines - therapeutic use | Creatinine - blood | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2016, Volume 3, Issue 9, pp. e410 - e420
Summary Background Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with... 
Infectious Disease | UNITED-STATES | INFECTIOUS DISEASES | TENOFOVIR DISOPROXIL FUMARATE | TREATMENT-NAIVE | ACTIVE ANTIRETROVIRAL THERAPY | CLINICAL-TRIALS | INITIAL TREATMENT | GENDER | SEX-DIFFERENCES | IMMUNOLOGY | HIV-1 INFECTION | ADVERSE EVENTS | Atazanavir Sulfate - administration & dosage | Humans | RNA, Viral - blood | Tenofovir - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Atazanavir Sulfate - adverse effects | Viral Load | Quinolones - adverse effects | Ritonavir - adverse effects | Quinolones - therapeutic use | Ritonavir - therapeutic use | Adult | Female | Emtricitabine - administration & dosage | HIV Protease Inhibitors - adverse effects | Emtricitabine - adverse effects | Emtricitabine - therapeutic use | Tenofovir - adverse effects | Double-Blind Method | Ritonavir - administration & dosage | Tenofovir - therapeutic use | HIV Infections - virology | Cobicistat - administration & dosage | International Cooperation | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active | Atazanavir Sulfate - therapeutic use | Quinolones - administration & dosage | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Cobicistat - adverse effects | HIV Infections - drug therapy | Cobicistat - therapeutic use
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2013, Volume 62, Issue 5, pp. 483 - 486
Journal Article